Package Leaflet: Information for the User
Tetraximinjectable suspension in pre-filled syringe
Diphtheria, tetanus, pertussis (acellular component) and poliomyelitis (inactivated) (adsorbed) vaccine
Read all of this leaflet carefully before your child is vaccinated because it contains
important information.
Contents of the package leaflet
Tetraxim is a vaccine (DTaP-IPV) used to protect against infectious diseases.
Tetraxim helps protect your child against diphtheria, tetanus, pertussis (whooping cough), and poliomyelitis.
It is administered as primary vaccination in children from 2 months of age and as a booster vaccine in children who received this vaccine or a similar one when they were younger.
When a Tetraxim injection is administered, the body's natural defenses produce protection against these different diseases.
Important
Tetraxim will only help prevent these diseases if they are caused by the same bacteria or viruses used to produce the vaccine. Your child may still contract infectious diseases if they are caused by other bacteria or viruses.
It is important that you inform your doctor, pharmacist, or nurse if any of the following points apply to your child so that they can make sure Tetraxim is suitable for your child.
Do not use Tetraxim
Warnings and precautions
Tell your doctor or nurse before vaccination:
After any injection with a needle, or even before, fainting can occur. Therefore, inform your doctor or nurse if you or your child has fainted with any previous injection.
Other medicines/vaccines and Tetraxim
Tetraxim can be administered at the same time as:
but in separate injection sites.
Ask your doctor or pharmacist for more information if your child is given Tetraxim at the same time as any of the other vaccines mentioned.
Tell your doctor or pharmacist if your child is using, has recently used, or might use any other medicines.
Pregnancy and breastfeeding
Not applicable. This vaccine is intended only for children.
Tetraxim contains phenylalanine, ethanol, and sodium.
Tetraxim contains 12.5 micrograms of phenylalanine in each 0.5 ml dose. Phenylalanine may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine accumulates because the body cannot eliminate it properly.
Tetraxim contains 2 mg of alcohol (ethanol) in each 0.5 ml dose. The small amount of alcohol in this medicine will not produce noticeable effects.
Tetraxim contains less than 1 mmol (23 mg) of sodium per dose, i.e., it is essentially "sodium-free".
Follow exactly the administration instructions of this medicine given by your doctor. If you are unsure, consult your doctor again.
Posology:
Primary vaccination and first booster dose:
The vaccination program includes primary vaccination, which consists of:
Additional booster vaccination
A booster dose is recommended between 4 and 13 years of age.
The use of this vaccine should be according to official recommendations.
Method of administration:
Vaccination should be administered by medically trained professionals or healthcare professionals trained in the use of vaccines and equipped to handle any unusual severe allergic reaction.
Tetraxim is administered as an injection into a muscle [intramuscularly (IM)] in the upper leg or arm of your child. The vaccine should never be administered into a blood vessel.
If your child misses a dose of Tetraxim
If your child misses a scheduled injection, your doctor will decide when to administer the missed dose.
If your child uses more Tetraxim than they should
Since your doctor or nurse administers Tetraxim to your child, it is unlikely that your child will receive too much Tetraxim. If you think that your child has received too much Tetraxim or the interval between two injections was too short, inform your doctor or nurse.
If you have any other questions about the use of this medicine, ask your doctor, nurse, or pharmacist.
Like all vaccines and medicines, Tetraxim can cause side effects, although not everybody gets them.
Severe allergic reactions
If any of these symptoms occur after leaving the place where your child received the injection, you must consult a doctor IMMEDIATELY.
The possibility of severe allergic reactions occurring after the administration of any vaccine is very rare (affects less than 1 in 10,000 people). These reactions can be:
When these signs and symptoms occur, they usually develop rapidly after the injection and while your child is still in the clinic or doctor's office.
Other side effects
If your child experiences any of the following side effects and they get worse or if you notice any side effect not mentioned in this leaflet, consult your doctor, nurse, or pharmacist.
Another reaction that may occur when Tetraxim is administered at the same time as another vaccine against Haemophilus influenzaetype b:
Potential side effects(i.e., the following side effects have not been directly reported with Tetraxim, but have been reported with other vaccines that contain one or more of the antigenic components of Tetraxim) are:
Reporting of side effects
If your child experiences any side effects, consult your child's doctor, pharmacist, or nurse, even if they are not listed in this leaflet. You can also report them directly through the Spanish Medicines Monitoring System for Human Use: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Store in a refrigerator (between 2°C and 8°C).
Do not freeze.
Do not use this medicine after the expiry date stated on the label and carton after EXP.
The expiry date is the last day of the month stated.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition of Tetraxim
A dose (0.5 ml) contains:
Diphtheria Toxoid1 not less than 20 UI2,3 (30 Lf)
Tetanus Toxoid1 not less than 40 UI3,4 (10 Lf)
Bordetella pertussisantigens
Pertussis Toxoid1 25 micrograms
Filamentous Hemagglutinin1 25 micrograms
Inactivated Poliovirus 5
Type 1 (Mahoney)4 29 units of antigen D6
Type 2 (MEF-1)4 7 units of antigen D6
Type 3 (Saukett) 4 26 units of antigen D6
1 Adsorbed on hydrated aluminum hydroxide (0.3 milligrams Al3+)
2 As a lower confidence limit (p = 0.95) and not less than 30 UI as a mean value
3 Or equivalent activity determined by immunogenicity evaluation
4 As a lower confidence limit (p = 0.95)
5 Grown in Vero cells
6 These antigen quantities are strictly the same as those previously expressed as 40-8-32 units of antigen D, for virus types 1, 2, and 3, respectively, when measured by another suitable immunochemical method.
This vaccine includes aluminum hydroxide as an adjuvant. Adjuvants are substances included in certain vaccines to accelerate, enhance, and/or prolong the protective effects of the vaccine.
The vaccine may contain traces of glutaraldehyde, neomycin, streptomycin, and polymyxin B used during the manufacturing process.
Appearance of the Product and Container Contents
Tetraxim, injectable suspension, is available in a single-dose pre-filled syringe (0.5 ml).
Container sizes of 1 or 10 without a needle, with a fixed needle, with 1 separate needle, or with 2 separate needles.
Only some container sizes may be marketed.
Marketing Authorization Holder and Manufacturer
The marketing authorization holder is:
Sanofi Winthrop Industrie
82 avenue Raspail
94250 Gentilly
France
The manufacturer is:
Sanofi Winthrop Industrie
1541 avenue Marcel Mérieux
69280 Marcy l’Etoile
France
or
Sanofi Winthrop Industrie
Voie de l’Institut – Parc Industriel d’Incarville
B.P 101
27100 Val de Reuil
France
Local Representative
sanofi-aventis, S.A.
C/ Rosselló i Porcel, 21
08016 Barcelona
Spain
Tel: +34 93 485 94 00
This medicinal product is authorized in the Member States of the European Economic Area under the following names:
Tetraxim: Croatia, Cyprus, Czech Republic, Hungary, Poland, Slovakia, Spain.
Date of the last revision of this leaflet: 08/2024
Detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
-------------------------------------------------------------------------------------------------------------------------
This information is intended solely for healthcare professionals:
Instructions for use - Tetraxim, injectable suspension
Diphtheria, tetanus, pertussis (acellular component), and poliomyelitis (inactivated) vaccine, adsorbed.
For syringes without a fixed needle, the separate needle should be firmly attached to the syringe, turning it a quarter turn.
Shake before injection until a homogeneous, whitish-turbid suspension is obtained.
The suspension should be visually inspected before administration. If foreign particles and/or a change in physical appearance are observed, the pre-filled syringe should be discarded.
Tetraxim can be administered by reconstituting the Act-HIB vaccine (Haemophilus influenzae type b conjugate) as follows:
Shake the pre-filled syringe until the contents become homogeneous and reconstitute the solution by injecting the suspension of the combined vaccine against diphtheria, tetanus, pertussis, and poliomyelitis into the vial with the powder of the conjugate vaccine against Haemophilus type b.
In this case, the syringe should be shaken again vigorously before administration.
Tetraxim should be administered intramuscularly. The recommended injection sites are the anterolateral aspect of the upper thigh in infants and the deltoid muscle in older children.